Вакцина RhACE2 APN01
Международное непатентованное наименование
Вакцина RhACE2 APN01
Торговое наименование
-
Производитель, страна
APEIRON Biologics AG, Austria
Опыт использования
A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). This synthetic version of the human protein that the novel coronavirus uses to enter cells is being tested in Austria to see if it can block viral entry and decrease viral replication in COVID-19 patients, reducing deaths or need for mechanical ventilation. Preliminary results from the trial that was announced on April 2 are expected in September 2020.
Клинические исследования
1.
Название протокола
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Дата начала и окончания КИ
April 2020 - November 2020
Название организации, проводящей КИ
Apeiron Biologics
Страны
Austria, Denmark, Germany
Фаза
II
Кол-во пациентов
200
2.
Название протокола
A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19
Дата начала и окончания КИ
February 2020 - April 2020
Название организации, проводящей КИ
The First Affiliated Hospital of Guangzhou Medical University
Страны
China
Фаза
-
Кол-во пациентов